Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 11/20 | 0.47 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563098 | 0.90 | CYP17A1 (0.47) | CYP17A1CYP24A1CYP19A1 | |
| SCHEMBL8214431 | 0.84 | CYP17A1 (0.50) | CYP17A1CYP24A1CYP26A1SLC6A4SLC6A3 | |
| SCHEMBL7568524 | 0.79 | PTGS2 (0.50) | CYP17A1CYP19A1SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL7653706 | 0.74 | PTGS2 (0.47) | CYP26A1SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL7563888 | 0.72 | FNTA (0.46) | — | |
| SCHEMBL7561820 | 0.72 | PTGS2 (0.52) | CYP26A1CYP19A1SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL7565357 | 0.70 | FNTA (0.44) | CYP24A1CYP19A1 | |
| SCHEMBL7240643 | 0.69 | SLC6A3 (0.58) | SLC6A4SLC6A3 | |
| SCHEMBL7563092 | 0.68 | PTGS2 (0.52) | CYP17A1CYP19A1SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL8197258 | 0.67 | CYP17A1 (0.49) | CYP17A1CYP24A1CYP26A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | CYP17A1 281/4885CYP24A1 1278/4885CYP26A1 602/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | CYP17A1 298/4885CYP24A1 1474/4885CYP26A1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.